Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Surgery
Link
https://link.springer.com/content/pdf/10.1245/s10434-023-14082-2.pdf
Reference17 articles.
1. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81. https://doi.org/10.1200/JCO.2007.14.4147. (Epub 2008 Feb 4 PMID: 18250347).
2. Golshan M, Loibl S, Wong SM et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial. JAMA Surg. 2020;155(3):e195410. doi: https://doi.org/10.1001/jamasurg.2019.5410. Epub 2020 Mar 18. Erratum in: JAMA Surg. 2021;156(5):503. PMID: 31913413; PMCID: PMC6990971.
3. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61. https://doi.org/10.1001/jama.2013.278932.
4. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230(1):72–8. https://doi.org/10.1097/00000658-199907000-00011. (PMID:10400039;PMCID:PMC1420847).
5. Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591–601. https://doi.org/10.1097/SLA.0000000000002953.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ASO Author Reflections: Exploring Discordant Response to Neoadjuvant Therapy in Breast Cancer: Insights into the Clinical and Biological Implications of Persistent Lymph Node Metastasis;Annals of Surgical Oncology;2023-10-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3